The corona pandemic has brought companies into the focus of a broad public, the importance of which had previously only been appreciated by those familiar with the industry. One of them is the Mainz group Schott. Its subsidiary Schott Pharma delivered many millions of vials, the bottles in which the vaccine against the corona virus was filled. The parent company announced on Wednesday that the company is to go public by the end of the year, and that it intends to retain the majority of the capital. No new shares are to be placed for the IPO, which means that Schott Pharma itself will not receive any money.
The IPO has been in the offing for a long time. Schott Pharma manufactures ampoules, vials and syringes made of glass and plastic for the pharmaceutical industry – around 13 billion of them every year. On average, more than 25,000 injections are given to patients every minute using a Schott Pharma product. In the first nine months of the 2022/2023 financial year, Schott Pharma increased sales by a good eight percent to EUR 670 million. The operating profit (Ebitda) increased by a good nine percent to almost 190 million euros. The Handelsblatt quotes people familiar with the matter, according to which the valuation of Schott Pharma is around four billion euros.